Refractory Tumor clinical trials at UCSF

1 research study open to eligible people

A refractory tumor does not respond to standard treatments. UCSF is testing a drug called 9-ING-41 to see if it can help children with these tough cancers. This study checks if the drug works well and is safe for young patients.

Showing trials for

  • 9-ING-41 in Pediatric Patients with Refractory Malignancies.

    open to eligible people ages up to 22 years

    9-ING-41 has anti-cancer clinical activity with no significant toxicity in adult patients. This Phase 1 study will study its efficacy in paediatric patients with advanced malignancies.

    San Francisco, California and other locations

Our lead scientists for Refractory Tumor research studies include .

Last updated: